Navigation Links
Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
Date:2/28/2011

T-cell levels and no detectable viral load on long-term HAART.  The trial has three dosing cohorts.  Subjects will remain on their existing antiviral therapy while receiving treatment with SB-728-T. A fourth cohort, of up to four subjects who have failed HAART and have measureable viral loads, was recently added to the study.  No data from subjects in the last two cohorts of this study were reported in today's CROI presentation. The primary objective of the study is to evaluate the safety and tolerability of SB-728-T. In addition to safety monitoring, data are being collected on the expansion, trafficking and persistence of SB-728-T, total CD4+ T-cell counts, CD4:CD8 T-cell ratios and viral load.

Dr. June has no financial relationship with Sangamo BioSciences, Inc.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has a Phase 1 / 2 clinical trial and two ongoing Phase 1 clinical trials to evaluate the safety and efficacy for the treatment of HIV/AIDS as well as a Phase 1 trial for the treatment for recurrent glioblastoma multiforme. Other therapeutic programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... announced that interim chief executive officer Howie Rosen ... and chief financial officer Tim Morris will ... of the two presentations are as follows: ...
(Date:5/21/2015)... 2015 Research and Markets ... the "North American Active Wound Care Market ... Wound, & Ulcer), by End-User (In-Patient, & Out-Paient) ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The ... to grow at a CAGR of 3.1% from ...
(Date:5/21/2015)...  Cardica, Inc. (Nasdaq: CRDC ) today announced that ... the company,s vice president of operations, was granted an option ... a per share exercise price of $0.43, the closing trading ... pursuant to Cardica, Inc.,s Inducement Plan, which was approved by ... 5653(c)(4) of the Nasdaq Global Market for equity grants to ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2Cardica Announces New Employment Inducement Grant 2
... Total quarterly revenues of $608 million increase 53 percent versus prior year; ... for prior year; Adjusted diluted EPS of $1.05 ... increases 2011 revenue guidance to a range of $2.72 to $2.80 billion; and ... a range of $4.55 to $4.65 and Reported or GAAP diluted EPS to ...
... Intercept Pharmaceuticals, Inc. (Intercept) and Les Laboratoires Servier ... worldwide ex-U.S. and Japan agreement for the discovery and ... type 2 diabetes and other metabolic indications. The collaboration ... proprietary bile acid analog chemistry and expertise targeting TGR5 ...
Cached Medicine Technology:Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 2Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 3Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 4Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 5Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 6Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 7Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 8Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 9Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 10Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 11Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 12Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 13Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 14Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 15Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 16Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 17Intercept Pharmaceuticals and Servier Announce Agreement for Intercept's TGR5 Research Program in Type 2 Diabetes 2Intercept Pharmaceuticals and Servier Announce Agreement for Intercept's TGR5 Research Program in Type 2 Diabetes 3
(Date:5/24/2015)... 24, 2015 A report out ... the single best option for avoiding cardiovascular disease is ... level was the single most powerful predictor of death ... as diabetes and family history of premature death -- ... heart and lung fitness. , The Importance of Cardiovascular ...
(Date:5/23/2015)... May 23, 2015 On May 13, ... of a youngster's yogic power learned through meditation and ... Swami in Bangalore, India. , Yogamaatha, a nine-year-old girl ... 50 high profile professionals attending the 2015 Business Advocacy ... fluently -- blindfolded. , In a demonstration that ...
(Date:5/23/2015)... Diego, CA (PRWEB) May 23, 2015 ... especially small businesses, are finding it increasingly difficult to ... businesses which fail to provide adequate insurance for employees ... for businesses been such an integral part of a ... more affordable healthcare for businesses, Online USA Doctors has ...
(Date:5/23/2015)... CO (PRWEB) May 23, 2015 On May ... in MuckFest. The event was a 5k mud obstacle run ... more than 2 million people worldwide, and the reason we ... community,” said Chad Davis, owner of Farrell’s eXtreme Bodyshaping. “One-hundred ... Multiple Sclerosis Society.” , The event was not only attended ...
(Date:5/23/2015)... May 23, 2015 A live auction will ... from hospitals, surgery centers and other medical facilities around the ... including endoscopy, lab, radiology, surgery, anesthesia, exam and much more. ... 27 and Thursday, May 28 starting at 9:00am CDT each ... 1400 N. 25th Avenue, Melrose Park, IL 60160. Anyone ...
Breaking Medicine News(10 mins):Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2
... doctor was acquitted on Wednesday of murdering three of his ... Martin, 71, a retired army officer from North Wales, was ... the lives of three seriously ill men, after a six-week ... look into the deaths of other patients under the care ...
... the first to visualize a need for laboratories in the Mexican ... Sustainability Laboratory (BNSL), which extends over an area of 4000 square ... security force and deal with terrorism // with the help ... for the lab come from USA, State of New Mexico and ...
... Barry D. Weiss, professor of family and community medicine and ... among patients. // ,They developed a tool which is ... minute questionnaire with six questions based on an ice cream ... by the patient their health literacy can be calculated. ...
... Gabriella gobbi and his team from Universite de ... increases the level of endocannabinoids by blocking the ... are chemicals present in brain which is responsible ... brain receptors are triggered during exercises and other ...
... Internal Medicine this week have found that the standard ... kidney failure is useless. //The study conducted by researchers ... found that a treatment called "plasma exchange" in patients ... means that the money which is currently spent in ...
... study conducted by the University of Alberta has revealed that ... mental health before its parents divorce. //The study does not ... More attention should be paid to the child while the ... the event has already occurred, according to Dr. Lisa Strohschein. ...
Cached Medicine News:Health News:British Doctor cleared of murder 2
... Antigen (PSA) derives its name from its ... gland. The majority of PSA circulates ... Serum concentrations of PSA are elevated ... hypertrophy (BPH) and prostatitis [1-3]. In addition, ...
... profitability by reducing ... simple test,sequences that ... by ancillary office ... 5 minutes. New ...
Vision Testing for Infants and Non-Verbal Patients,Using Preferential Looking....
Pediatric: Tumbling "E" Acuity, Binocular Balance, Supression, Fixation Disparity, Stereopsis...
Medicine Products: